Full Text

Turn on search term navigation

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The use of particles for monocyte-mediated delivery could be a more efficient strategy and approach to achieve intracellular targeting and delivery of antitubercular drugs to host macrophages. In this study, the potential of inulin microparticles to serve as a drug vehicle in the treatment of chronic tuberculosis using a monocytes-mediated drug targeting approach was evaluated. Isoniazid (INH) was conjugated to inulin via hydrazone linkage in order to obtain a pH-sensitive inulin-INH conjugate. The conjugate was then characterized using proton nuclear magnetic resonance (1HNMR), Fourier transform infrared spectroscopy (FTIR) as well as in vitro, cellular uptake and intracellular Mycobacterium tuberculosis (Mtb) antibacterial efficacy. The acid-labile hydrazone linkage conferred pH sensitivity to the inulin-INH conjugate with ~95, 77 and 65% of the drug released after 5 h at pH 4.5, 5.2, and 6.0 respectively. Cellular uptake studies confirm that RAW 264.7 monocytic cells efficiently internalized the inulin conjugates into endocytic compartments through endocytosis. The intracellular efficacy studies demonstrate that the inulin conjugates possess a dose-dependent targeting effect against Mtb-infected monocytes. This was through efficient internalization and cleavage of the hydrazone bond by the acidic environment of the lysosome, which subsequently released the isoniazid intracellularly to the Mtb reservoir. These results clearly suggest that inulin conjugates can serve as a pH-sensitive intracellular drug delivery system for TB treatment.

Details

Title
Synthesis and Characterization of pH-Sensitive Inulin Conjugate of Isoniazid for Monocyte-Targeted Delivery
Author
Franklin Afinjuomo 1 ; Barclay, Thomas G 1   VIAFID ORCID Logo  ; Parikh, Ankit 1 ; Chung, Rosa 1 ; Song, Yunmei 1 ; Nagalingam, Gayathri 2 ; Triccas, Jamie 2 ; Wang, Lixin 1 ; Liu, Liang 1 ; Hayball, John D 1 ; Petrovsky, Nikolai 3   VIAFID ORCID Logo  ; Garg, Sanjay 1   VIAFID ORCID Logo 

 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia 5001, Australia; [email protected] (F.A.); [email protected] (T.G.B.); [email protected] (A.P.); [email protected] (R.C.); [email protected] (Y.S.); [email protected] (L.W.); [email protected] (L.L.); [email protected] (J.D.H.) 
 Tuberculosis Research Program, Centenary Institute, University of Sydney, Sydney, NSW 2006, Australia; [email protected] (G.N.); [email protected] (J.T.) 
 Vaxine Pty. Ltd., Adelaide, SA 5042, Australia; [email protected]; College of Medicine and Public Health, Flinders University, Adelaide, SA 5042, Australia 
First page
555
Publication year
2019
Publication date
2019
Publisher
MDPI AG
e-ISSN
19994923
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2550227667
Copyright
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.